{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:42:39Z","timestamp":1793893359638,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.esmoop.2021.100213","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T23:14:41Z","timestamp":1626218081000},"page":"100213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["How we treat primary central nervous system lymphoma"],"prefix":"10.1016","volume":"6","author":[{"given":"T.","family":"Calimeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Steffanoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100213_bib1","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","first-page":"300","article-title":"Primary diffuse large B-cell lymphoma of the CNS","author":"Kluin","year":"2017"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100213_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Shiels","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100213_bib3","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2967\/jnumed.120.241703","article-title":"CXCR4-targeted PET imaging of central nervous system B-cell lymphoma","volume":"61","author":"Herhaus","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100213_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.17357","article-title":"MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study","volume":"193","author":"Ferreri","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100213_bib5","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1016\/j.esmoop.2021.100213_bib6","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100213_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Supp 2","key":"10.1016\/j.esmoop.2021.100213_bib8","article-title":"MATRIX induction followed by autologous stem cell transplant or whole-brain irradiation in Primary CNS Lymphoma. 7-year results of the IELSG32 randomized trial. Abstract 047_16th ICML","volume":"39","author":"Ferreri","year":"2021","journal-title":"Haemat Oncol"},{"key":"10.1016\/j.esmoop.2021.100213_bib9","first-page":"noab021","article-title":"Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105\/ALLG NHL 24 randomised controlled trial","author":"van der Meulen","year":"2021","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100213_bib10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100213_bib11","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an\u00a0intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100213_bib12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/leu.2016.334","article-title":"High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume":"31","author":"Fritsch","year":"2017","journal-title":"Leukemia"},{"issue":"31","key":"10.1016\/j.esmoop.2021.100213_bib13","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100213_bib14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3324\/haematol.2014.108472","article-title":"Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the\u00a0Nordic Lymphoma Group","volume":"100","author":"Pulczynski","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100213_bib15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/bmt.2017.23","article-title":"High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients\u00a0with primary central nervous system lymphoma: a European\u00a0retrospective study","volume":"52","author":"Schorb","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100213_bib16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2021.100213_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.esmoop.2021.100213_bib18","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.esmoop.2021.100213_bib19","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100213_bib20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR\u00a0T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1016\/j.esmoop.2021.100326","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000}}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T01:18:06Z","timestamp":1668820686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921001745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2059702921001745"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100213","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How we treat primary central nervous system lymphoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100213"}}